Advanced Cell Technology Appoints Executive VP of Clinical Development

Advanced Cell Technology Inc. has appointed Eddy Anglade, M.D., to the newly created position of executive vice president of Clinical Development. Anglade is an ophthalmologist and a pharmaceutical executive with more than 16 years of experience overseeing all elements of clinical trials and regulatory affairs.

“We created the new position, EVP of Clinical Development, as we prepare for our transition to Phase II of our AMD [Age-Related Macular Degeneration] and SMD [Stargardt’s Macular Dystrophy] clinical trials. We are thrilled to welcome such an experienced and accomplished executive to our team at this critical point in the company’s evolution,” CEO Gary Rabin said. “Dr. Anglade has extensive experience in the development of therapeutics for treating diseases of the eye. He will make an excellent addition to the management team at ACT as the company continues to work with its clinical development partners.”

Anglade joins ACT after co-founding Lux Pharmaceuticals and serving as its chief medical officer, where he guided the development of orphan designated and fast-track products as well as early phase development of a novel therapeutic agent for dry eye disease. His responsibilities included recruitment and development of the clinical operations, program management, and medical writing teams, as well as serving as the safety officer responsible for review of all studies.

Previously he was vice president of Clinical Development at Enzon Pharmaceuticals, where he oversaw all clinical development activities and was a member of the research and development leadership team, and designed the industry’s first multi-center, randomized, placebo-controlled and blinded study of an agent for the prevention of rejection in lung transplantation. He served as a medical director for Hoffman-La Roche Inc., where he developed and implemented clinical strategies for the CellCept and Cytovene drugs and served as the medical monitor for Zenapax in cardiac transplantation.

Anglade holds an M.D. from Yale University. He completed his residency in ophthalmology at Massachusetts Eye and Ear Infirmary/Harvard Medical School, and received additional training in ocular immunology at the National Eye Institute/National Institutes of Health. He is an extensively published author in eye disease and immunology.

“ACT is a great opportunity. The data from the Phase I AMD and SMD trials are very encouraging. I am excited to join the team and look forward to helping in guiding the clinical and regulatory strategy as the company progresses through its clinical trials,” Anglade said. “Macular degenerative diseases represent large and important unmet medical needs.”

Based in Marlborough, Mass., Advanced Cell Technology develops and commercializes human embryonic and adult stem cell technology for regenerative medicine applications. The company is conducting several clinical trials for treating macular degeneration, and has a preclinical development pipeline focused on products for eye diseases, autoimmune and inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent stem cell platforms comprising embryonic stem cell and induced pluripotent stem cell platforms; and other cell therapy research programs.